US Bancorp DE Increases Position in Genmab A/S (NASDAQ:GMAB)

US Bancorp DE lifted its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 16.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 171,669 shares of the company's stock after purchasing an additional 23,723 shares during the quarter. US Bancorp DE's holdings in Genmab A/S were worth $4,185,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its position in Genmab A/S by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,064 shares of the company's stock worth $197,000 after acquiring an additional 3,137 shares during the period. Legacy Wealth Asset Management LLC lifted its position in Genmab A/S by 1.1% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company's stock worth $1,097,000 after acquiring an additional 471 shares during the period. Mediolanum International Funds Ltd acquired a new stake in Genmab A/S during the 3rd quarter worth approximately $699,000. Mount Yale Investment Advisors LLC acquired a new stake in Genmab A/S during the 3rd quarter worth approximately $192,000. Finally, International Assets Investment Management LLC acquired a new stake in Genmab A/S during the 3rd quarter worth approximately $254,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on GMAB shares. Royal Bank of Canada raised Genmab A/S from a "sector perform" rating to an "outperform" rating in a research report on Monday, July 15th. Redburn Atlantic assumed coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a "buy" rating for the company. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Finally, Morgan Stanley reissued an "equal weight" rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $45.20.

Genmab A/S Trading Down 0.1 %

NASDAQ:GMAB traded down $0.03 during mid-day trading on Tuesday, hitting $22.75. The company had a trading volume of 1,636,247 shares, compared to its average volume of 662,001. The business has a fifty day simple moving average of $24.78 and a 200-day simple moving average of $26.54. Genmab A/S has a 1 year low of $22.18 and a 1 year high of $32.89. The firm has a market capitalization of $15.06 billion, a price-to-earnings ratio of 18.83, a PEG ratio of 0.67 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The company had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. As a group, research analysts anticipate that Genmab A/S will post 1.29 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.